US5021235A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preparation of rhenium phosphonate therapeutic agents for bone cancer without purification
Assignee: Mallinckrodt Inc
•
Filing: 1989-05-02
•
Granted: 1991-06-04
•
Expires: 2009-05-02
Abstract
Abstract The process of the present invention includes preparing a first aqueous solution of rhenium in the form of radioactive perrhenate, wherein the concentration of rhenium in said solution is within the range of about 5×10 -6 M to about 2×10 -3 M, and then reducing and complexing the radioactive perrhenate by mixing a second solution or lyophilized solid with the first solution. The second solution or lyophilized solid comprises a ligand which complexes with the radioactive perrhenate and a reductant wherein the reductant is present in the second solution at a concentration in the range of about 0.005M to about 0.020M and the ligand is present in the second solution at a concentration in the range of about 0.01M and about 0.15M. The pH of the resultant solution is within the range of about 1.5 to about 5.5.
Inventors
- 👤 David W. Pipes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 13:28
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0478; A61K51/0489; A61P; A61P35/00; C; C07; C07B; C07B59/00; A61K2123/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
145 words
A process for preparing a rhenium therapeutic agent which does not require purification prior to administration comprising: (a) preparing a first aqueous solution of rhenium in the form of radioactive perrhenate, the concentration of rhenium in said solution within the range of about 5×10 31 6 M to about 2×10 -3 M; and (b) reducing and complexing the radioactive perrhenate by mixing the first solution with either a second solution or a lyophilized solid form thereof, said second solution or said solid comprising a ligand which complexes with the radioactive perrhenate and a reductant wherein the reductant is present at a concentration in the range of about 0.005M to about 0.020M and the ligand is present at a concentration in the range of about 0.01M to about 0.15M; wherein the pH of the resultant solution is within the range of about 1.5 to about 5.5.
Claim 2
Dependent Claim
145 words
A process for preparing a rhenium therapeutic agent which does not require purification prior to administration comprising: (a) preparing a first aqueous solution of rhenium in the form of radioactive perrhenate, the concentration of rhenium in said solution within the range of about 5×10 31 6 M to about 2×10 -3 M; and (b) reducing and complexing the radioactive perrhenate by mixing the first solution with either a second solution or a lyophilized solid form thereof, said second solution or said solid comprising a ligand which complexes with the radioactive perrhenate and a reductant wherein the reductant is present at a concentration in the range of about 0.005M to about 0.020M and the ligand is present at a concentration in the range of about 0.01M to about 0.15M; wherein the pH of the resultant solution is within the range of about 1.5 to about 5.5.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the radioactive perrhenate contains either Re 186 or Re 188 .
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein the pH is between 2.0 and 2.5.
Claim 5
Dependent Claim
17 words
A process according to claim 1 wherein said second solution of lyophilized solid further comprises an antioxidant.
Claim 6
Dependent Claim
12 words
A process according to claim 1 wherein the reductant is stannous chloride.
Claim 7
Dependent Claim
13 words
The method of claim 1 wherein the ligand is a bone seeking ligand.
Claim 8
Dependent Claim
17 words
The method of claim 6 wherein the ligand is a polyphosphate, pryophosphate, phosphonate, diphosphonate, phosphonite or imidodiphosphate.
Claim 9
Dependent Claim
11 words
The method of claim 7 wherein the ligand is a diphosphonate.
Claim 10
Dependent Claim
12 words
The method of claim 8 wherein the ligand is 1- hydroxyethylidene diphosphonate.
References Cited (Backward Citations)
US3192011A
Cited
US3983227A
Cited
US4652440A
Cited
US4778672A
Cited
EP0250966A1
Cited
US4925925A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-06-03 | 1994-12-03 | 1995-06-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-06-03 | 1998-12-03 | 1999-06-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-06-03 | 2002-12-03 | 2003-06-04 | $7700.00 | Window Closed / Lapsed |